Tech Company Financing Transactions
Viracta Therapeutics Funding Round
On 10/28/2019, Viracta Therapeutics raised Series D funding from Taiwania Capital and private investors.
Transaction Overview
Company Name
Announced On
10/28/2019
Transaction Type
Venture Equity
Amount
Unknown
Round
Series D
Investors
Taiwania Capital (Lead Investor) (Michael Huang)
Proceeds Purpose
Proceeds from the financing are expected to be used to complete the Phase 2 study and subsequent initiation of registration studies, as well as for other general corporate purposes. Additionally, the Company intends to pursue the application of its Kick and Kill approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, and other virus-related cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2533 S. Coast Hwy. 101 210
Cardiff, CA 92007
USA
Cardiff, CA 92007
USA
Phone
Website
Email Address
Overview
Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Douglas Faller
Chief Executive Officer
Ivor Royston
Chief Medical Officer
Marshelle Warren
VP - Bus. Development
David Slack
VP - R & D
Robert McRae
Browse more venture capital transactions:
Prev: 10/28/2019: PierianDx venture capital transaction
Next: 10/28/2019: PeerStreet venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs